Actelion Pharmaceuticals Ltd

Actelion Pharmaceuticals Ltd (VTX:ATLN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Actelion Pharmaceuticals Ltd (SWF:ATLN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Total net revenues of CHF 1,069.6 million, up 21 percent in local currencies and 13 percent in Swiss Francs - Tracleer® sales of CHF 945.8 million, up 21 percent in local currencies and 12 percent in Swiss Francs - Cash EBIT of CHF 355.6 million, up 18 percent in local currencies and 2 percent in Swiss Francs - Strong cash generation enables full funding of maturing pipeline - Upgraded 2008 guidance

Actelion Pharmaceuticals Ltd (SWF:ATLN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion senior management to host Q & A session.

Actelion Pharmaceuticals Ltd (SWF:ATLN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Total net revenues of CHF 676.0 million - Product sales up 18 percent in local currencies compared to H1 2007 - Tracleer® sales of CHF 605.2 million - Cash EBIT of CHF 190.8 million - Multiple Phase III studies on track - Substantial impact from Actelion/GSK orexin receptor antagonist collaboration to start immediately in H2 2008

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion senior management to host Q & A session

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion and GlaxoSmithKline (GSK) to potentially co-develop and co-commercialise other orexin receptor antagonists

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion and GlaxoSmithKline enter into exclusive collaboration to realize the full potential of almorexant in sleep disorders and beyond

Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------